Seeking Alpha

Durata Therapeutics (DRTX)

DRTX is defunct.
  • Oct. 6, 2014, 8:37 AM
    • Actavis (NYSE:ACT) acquires Durata Therapeutics (NASDAQ:DRTX) for $675M ($23/share) in cash and contingent value rights entitling the holder to receive up to an additional $5 per share if certain Dalvance (dalbavancin)-related regulatory or commercial milestones are met. Actavis expects the acquisition to be accretive by the end of the first year.
    | Oct. 6, 2014, 8:37 AM | 6 Comments
Company Description
Durata Therapeutics Inc is a development stage biopharmaceutical company. The Company, along with its subsidiaries, develops and commercializes novel therapeutics for patients with infectious diseases and acute illnesses.